Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-08-28

Clinical Trial Update: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial of dupilumab in adults with moderate-to-severe atopic dermatitis completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2017-08-28